Clinical trials: Post-Polycythemia Vera MF (Post-PV-MF)
Myelofibrosis, Primary Myelofibrosis
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
- Trial name
- NCT04551066
- Testing
- parsaclisib, ruxolitinib
- Where
- 177 sites in United States, Austria and 15 more
- Volunteers
- 252 people
- Sponsor
- Incyte Corporation
Primary Myelofibrosis
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT04446650
- Testing
- Fedratinib
- Where
- 21 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT07340138
- Testing
- Pelabresib, Ruxolitinib
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
MPN (Myeloproliferative Neoplasms)
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
- Trial name
- NCT01633372
- Testing
- itacitinib
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 87 people
- Sponsor
- Incyte Corporation
Myelofibrosis
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib.
- Trial name
- NCT04485260
- Testing
- KRT-232, Ruxolitinib
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 36 people
- Sponsor
- Kartos Therapeutics, Inc.
Primary Myelofibrosis
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
J8G-MC-JDIA (AJX-101) is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and changes in…
- Trial name
- NCT06343805
- Testing
- LY5830966
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 256 people
- Sponsor
- Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF)
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543)…
- Conditions
- Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF), Primary Myelofibrosis (PMF)
- Trial name
- NCT03136185
- Testing
- Bomedemstat
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 90 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to…
- Conditions
- Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations
- Trial name
- FM-MF-02 (NCT07750574)
- Testing
- Flonoltinib Maleate orally
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF
Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF.
- Conditions
- Primary Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Post-Essential Thrombocythemia (ET) MF
- Trial name
- NCT01392443
- Testing
- Ruxolitinib
- Where
- 26 sites in China, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis, Myelofibrosis
Study of Select Combinations in Adults With Myelofibrosis
The purpose of this study is to investigate the safety, pharmacokinetics (PK) and preliminary efficacy of both the combination of MBG453 and NIS793 with or without decitabine or spartalizumab as well as single agent MBG453 and/or…
- Conditions
- Primary Myelofibrosis, Myelofibrosis, PMF, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT04283526
- Testing
- MBG453, NIS793, Spartalizumab
- Sponsor
- Novartis Pharmaceuticals
Myelofibrosis
A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis
The purpose of this phase Ib clinical trial is to evaluate the safety of the combination of INC424 and BKM120 in the myelofibrosis population and to establish the maximum tolerated dose and or the Recommended Phase II dose of the…
- Trial name
- NCT01730248
- Testing
- INC424, BKM120
- Where
- 15 sites in Australia, Austria and 7 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF)
Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib.
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
- Trial name
- NCT04217993
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis
Extended Access of Momelotinib in Adults With Myelofibrosis
This is an extended-access, long-term safety study for participants with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF) who have not…
- Trial name
- NCT03441113
- Testing
- Momelotinib
- Where
- 112 sites in United States, Australia and 18 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF)
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
- Trial name
- BOREAS (NCT03662126)
- Testing
- KRT-232, Best Available Therapy (BAT)
- Where
- 191 sites in United States, Argentina and 26 more
- Volunteers
- 385 people
- Sponsor
- Kartos Therapeutics, Inc.
Myelofibrosis
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
This is a Phase IB, open-label, dose-finding study of the JAK 1 and 2 inhibitor ruxolitinib in patients with myelofibrosis (MF).
- Trial name
- NCT01317875
- Testing
- Ruxolitinib
- Where
- 18 sites in United States, Austria and 6 more
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Myelofibrosis
A Safety and Tolerability Study of Jaktinib
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
- Trial name
- NCT05279001
- Testing
- Jaktinib Hydrochloride Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF)…
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
- Trial name
- MANIFEST-3 (NCT07357727)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 164 sites in United States, Argentina and 20 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
MPN (Myeloproliferative Neoplasms)
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
To evaluate the effects of treatment with ruxolitinib (INCB018424) on spleen volume, symptoms and potential side effects in participants with PMF, PPV-MF and PET-MF who have platelet counts of 50 x 10^9/L to 100 x 10^9/L.
- Trial name
- NCT01348490
- Testing
- Ruxolitinib
- Where
- 38 sites in United States
- Volunteers
- 66 people
- Sponsor
- Incyte Corporation
Myelofibrosis, Primary Myelofibrosis
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi).
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- MANIFEST-2 (NCT04603495)
- Testing
- Pelabresib, Ruxolitinib
- Where
- 156 sites in United States, Australia and 20 more
- Volunteers
- 430 people
- Sponsor
- Novartis Pharmaceuticals